Please use this identifier to cite or link to this item:
|Title:||A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesity.|
|Authors:||Shoemaker, Ashley;Proietto, Joseph;Abuzzahab, M Jennifer;Markovic, Tania;Malloy, Jaret;Kim, Dennis D|
|Affiliation:||Division of Pediatric Endocrinology and Diabetes, Vanderbilt University Medical Center, Nashville, Tennessee|
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
McNeely Pediatric Diabetes Center and Endocrine Clinic, Children's Hospitals and Clinics of Minnesota, St. Paul, Minnesota
Boden Institute of Nutrition, Exercise & Eating Disorders, University of Sydney, Sydney, Australia
Zafgen Inc., Boston, Massachusetts..
|Citation:||Diabetes, obesity & metabolism 2017; 19(8): 1165-1170|
|Abstract:||Hypothalamic injury-associated obesity (HIAO) results from damage to the hypothalamus that often occurs with surgical removal/radiation therapy of tumours in the hypothalamic region, such as craniopharyngioma. There is currently no rigorously studied pharmaceutical treatment for the intractable weight gain and cardiometabolic consequences that occur in patients with HIAO. We aimed to assess efficacy, safety and tolerability of beloranib treatment for 4 to 8 weeks in patients with HIAO. This Phase 2a, double-blind, placebo-controlled study included 14 patients with HIAO, randomized to receive beloranib 1.8 mg or placebo subcutaneously twice weekly for 4 weeks with an optional 4-week open-label extension in which all patients received beloranib. The primary endpoint was change in weight from baseline to Week 4. Participants were 64% female, with a mean (SD) age of 32 (9) years, BMI of 43 (7) kg/m2 and weight of 126 (22) kg. Compared with placebo (N = 4), beloranib 1.8 mg (N = 8) resulted in a mean (95% CI) difference in weight of -3.2 (-5.4, -0.9) kg after 4 weeks. Weight loss continued through the 8 weeks in patients randomized to beloranib (mean -6.2 [-8.2, -4.1] kg). Beloranib treatment was associated with improvements in high-sensitivity CRP. Adverse events were mild to moderate. No patients who received beloranib discontinued treatment. Beloranib treatment resulted in progressive weight loss in patients with HIAO that was comparable to that observed with beloranib in patients with exogenous obesity. These findings indicate a novel mechanism for treating obesity in patients with HIAO.|
|Type:||Clinical Trial, Phase II|
Randomized Controlled Trial
phase I to II study
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.